Thorp Arch Estate
Unit 20 Ash Way
Wetherby LS23 7FA
United Kingdom
44 1904 217 070
https://www.avacta.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. David Alastair Maclaughlin Smith | CEO & Executive Director | 444k | N/A | 1966 |
Mr. Tony Gardiner | CFO, Company Secretary & Executive Director | 273k | N/A | 1971 |
Dr. Christina Marie Coughlin B.S., M.D., Ph.D. | Head of Research & Development, Interim Chief Medical Officer and Director | 37k | N/A | 1970 |
Ms. Emma Wright | Group In-House Counsel | N/A | N/A | N/A |
Mr. Michael Vinegrad | Group Communications Director | N/A | N/A | N/A |
Mr. R. Craig Slater FCA | Chief Operating Officer of Diagnostics | 69k | N/A | 1964 |
Dr. Matt Johnson | Chief Scientific Officer of Diagnostics | N/A | N/A | N/A |
Dr. Fiona McLaughlin FSB, Ph.D. | Chief Scientific Officer of Therapeutics Division | N/A | N/A | 1970 |
Mr. David Wilson | Chief Commercial Officer of Diagnostics | N/A | N/A | N/A |
Ms. Karen Harrison | Chief Operating Officer of Therapeutics Division | N/A | N/A | N/A |
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Avacta Group Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.